AbbVie Inc (NYSE:ABBV) – Analysts at Jefferies Group upped their FY2022 earnings per share estimates for shares of AbbVie in a note issued to investors on Tuesday. Jefferies Group analyst J. Holford now anticipates that the company will post earnings per share of $12.47 for the year, up from their prior estimate of $11.94. Jefferies Group currently has a “Buy” rating and a $120.00 price objective on the stock.

A number of other analysts have also weighed in on ABBV. Barclays reaffirmed a “hold” rating and issued a $68.00 price target on shares of AbbVie in a research note on Thursday, September 28th. BMO Capital Markets set a $84.00 price target on shares of AbbVie and gave the stock a “hold” rating in a research note on Thursday, January 11th. Evercore ISI reaffirmed an “outperform” rating and issued a $100.00 price target (up from $95.00) on shares of AbbVie in a research note on Saturday, September 30th. Zacks Investment Research raised shares of AbbVie from a “hold” rating to a “buy” rating and set a $115.00 price target for the company in a research note on Thursday. Finally, Credit Suisse Group reaffirmed a “neutral” rating and issued a $94.00 price target (up from $74.00) on shares of AbbVie in a research note on Sunday, October 1st. Six equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. AbbVie currently has an average rating of “Buy” and an average target price of $101.38.

Shares of AbbVie (NYSE:ABBV) traded down $0.55 during trading hours on Wednesday, hitting $103.81. 6,371,180 shares of the stock were exchanged, compared to its average volume of 4,510,000. The firm has a market cap of $165,480.00, a price-to-earnings ratio of 25.20, a P/E/G ratio of 1.23 and a beta of 1.53. AbbVie has a 12 month low of $59.27 and a 12 month high of $104.85. The company has a current ratio of 1.45, a quick ratio of 1.32 and a debt-to-equity ratio of 5.08.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, October 27th. The company reported $1.41 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.39 by $0.02. The firm had revenue of $7 billion during the quarter, compared to analyst estimates of $7 billion. AbbVie had a net margin of 24.38% and a return on equity of 153.80%. AbbVie’s revenue was up 8.8% on a year-over-year basis. During the same period in the previous year, the business posted $1.21 EPS.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, February 15th. Investors of record on Friday, January 12th will be issued a $0.71 dividend. This is an increase from AbbVie’s previous quarterly dividend of $0.64. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.74%. The ex-dividend date is Thursday, January 11th. AbbVie’s payout ratio is presently 68.93%.

In related news, SVP Timothy J. Richmond sold 87,040 shares of the business’s stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of $98.45, for a total value of $8,569,088.00. Following the sale, the senior vice president now directly owns 113,118 shares in the company, valued at approximately $11,136,467.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Laura J. Schumacher sold 145,510 shares of the business’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $96.71, for a total transaction of $14,072,272.10. The disclosure for this sale can be found here. Insiders sold a total of 494,676 shares of company stock worth $47,237,938 over the last quarter. Insiders own 0.23% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Acropolis Investment Management LLC acquired a new stake in shares of AbbVie during the second quarter valued at approximately $106,000. Hudock Capital Group LLC raised its holdings in shares of AbbVie by 109.5% during the second quarter. Hudock Capital Group LLC now owns 1,542 shares of the company’s stock valued at $111,000 after acquiring an additional 806 shares during the period. Ffcm LLC raised its holdings in shares of AbbVie by 167.2% during the second quarter. Ffcm LLC now owns 1,539 shares of the company’s stock valued at $111,000 after acquiring an additional 963 shares during the period. Bristlecone Advisors LLC acquired a new stake in shares of AbbVie during the third quarter valued at approximately $113,000. Finally, BDO Wealth Advisors LLC acquired a new stake in shares of AbbVie during the second quarter valued at approximately $115,000. Institutional investors and hedge funds own 69.19% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “AbbVie Inc Expected to Earn FY2022 Earnings of $12.47 Per Share (ABBV)” was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/abbvie-inc-expected-to-earn-fy2022-earnings-of-12-47-per-share-abbv/1812921.html.

AbbVie Company Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.